How do DSOs value a dental practice?

The letter of intent arrives and the number is wrong. Not catastrophically wrong, just lower than the one you have been carrying around in your head for years, the one built from a colleague's exit story and a broker's flattering estimate. If you are asking how DSOs value a dental practice, you are probably somewhere in that gap right now: between what you believe the practice is worth and what a buyer with a spreadsheet is willing to pay. The gap is not random. It follows a pattern, and the pattern repeats across 201,000+ US practices. This is what actually moves the number, and what only feels like it does.

What formula do DSOs actually use to value your practice?

Strip away the pitch decks and the process comes down to one line: adjusted EBITDA multiplied by a multiple. Adjusted EBITDA is your earnings after the buyer restates them, and the multiple is a grade the buyer assigns to how durable those earnings look without you. Everything else in diligence, the chart audits, the payer analysis, the visibility review, exists to move one of those two numbers.

Notice what is not in the formula. Not collections. Not chairs. Not the loyalty you feel from patients who have been with you for fifteen years. A practice collecting $2.4M with thin margins can be worth less than a practice collecting $1.6M that runs clean and refills its own schedule without the owner touching anything.

You built the practice from the inside, so you value the inputs: the hours, the equipment, the reputation. The buyer only prices the output, and only the portion of it that survives your departure. That single difference in vantage point explains most of the shock owners describe after a first offer. The number is not an insult. It is an answer to a question you were not asking.

Why does adjusted EBITDA come in lower than you expected?

Because the buyer's first move is to hire your replacement on paper. If you produce $900K a year and pay yourself through distributions, the DSO inserts a market-rate associate salary, often 30% of production or more, before counting a single dollar of earnings. Your income and the practice's earnings have been the same number your whole career. In the buyer's model, they are strangers.

Then the addbacks get audited. The vehicle, the conference travel, the family member on payroll: some survive, some do not, and every one that dies takes its multiple with it. A rejected $40K addback at a six-times multiple is $240K off the price, quietly, in a spreadsheet you may never see.

The pattern across owner exits is consistent: the practice you think you are selling earns more than the practice the DSO thinks it is buying. Neither of you is lying. You are measuring your life's work. They are measuring a cash flow that has to survive your absence, an associate's salary, and a regional manager's overhead. Knowing this before the letter arrives is the difference between negotiating and grieving.

What multiple range should you actually expect?

Multiples are a market, not a menu, but the bands are consistent enough to plan around. A single location with owner-dependent production typically trades in the low-to-mid single digits of adjusted EBITDA. A multi-location group with associates, systems, and durable patient flow moves into the high single digits. Platform-scale groups, the kind private equity builds around, can push higher still, because the buyer is purchasing infrastructure, not just earnings.

What moves you between bands is not size alone. It is transferability: whether the earnings arrive because of the machine or because of you personally.

The consolidation backdrop matters here too. DSOs already hold 32% of a $179.4B market, and they are not buying randomly. Your practice is being compared, in real time, against every other target in your region. You are not negotiating against the DSO's generosity. You are negotiating against the practice two miles away that runs the same collections with cleaner books and stronger patient flow. The band you land in is decided long before the management meeting, by how your practice looks sitting next to that one.

Which factors do you assume matter that barely move the number?

Owners walk into valuations carrying assets the model barely prices. The most common ones:

• Equipment and buildout. The CBCT, the new operatories, the renovation: buyers treat these as table stakes or replacement costs, not premiums. You paid for them with real money. The model prices them at almost nothing.
• Years in business. Longevity feels like proof of durability. To a buyer it can read as an aging patient base and relationships that walk out the door with you.
• Your personal reputation. The referrals that come because of your name are, from the buyer's chair, the least transferable asset in the building.
• Gross collections. Top-line revenue with weak margins is volume, not value, and buyers pay for value.

None of these are worthless. In the buyer's math, they are simply already spent on getting the practice to the starting line. What you are left negotiating with is the part you probably measured least: how predictably new patients find the practice without your name doing the work.

What do DSOs weight more heavily than you realize?

Three things dominate diligence conversations, and none of them hang on the wall.

First, provider capacity. With 33.9% of practices actively recruiting hygienists, a full, stable clinical team is scarce, and scarcity gets priced. Your intact hygiene department is worth more in the model than your renovation ever will be.

Second, recurring revenue quality. Hygiene reappointment rates, unscheduled treatment, active patient counts: the buyer reads these the way a subscription business reads churn. A practice that keeps patients cycling predictably is an annuity. One that survives on episodic emergencies is a lottery ticket.

Third, and this is the one that blindsides owners, demand capture. The buyer wants to know exactly how new patients arrive, and whether that pipeline is owned or rented. If new patient flow is a mystery even to you, it gets priced as fragile. If it demonstrably comes from durable visibility in Maps and AI search, it gets priced as infrastructure.

You have spent years assuming the clinical product was the asset. The buyer assumes clinical quality and prices the delivery system around it. That inversion is the valuation gap in one sentence.

How does patient acquisition visibility enter the valuation conversation?

Quietly, and then decisively. Every month, 432,000 dental searches run through AI platforms, and The Dental Index national practice audit found that 70% of practices are effectively invisible to those systems. Your buyer knows this, because your buyer runs the same visibility checks on you that they run on every target in the region.

Here is why it lands on the price. A DSO underwrites future patient flow. If your practice already surfaces when AI engines and Maps answer a patient asking for an implant dentist nearby, that flow is an asset the buyer inherits on day one. If it does not, the buyer models the cost of building it, and that cost comes out of your number.

The average practice scores below 40 out of 100 on AI readiness, and only 8% score above 65. Your score, whether you have ever seen it or not, is a line item in someone's model. Invisible practices do not get told they are invisible. They get a lower multiple with a polite explanation about growth investment required, and most owners never learn that the discount had a name.

What does your demand capture performance tell a buyer?

It tells them whether your growth is repeatable or lucky. The mechanics are visible from the outside: practices with complete Google Business Profiles earn 7x more clicks than incomplete ones, and 82% of dental searches end in a Maps interaction. A buyer can check both in an afternoon, without your permission, before you have signed anything.

What they are really evaluating is a demand capture system: the machinery that turns local search demand into booked chairs. When that machinery exists, the buyer sees earnings with a floor under them. When it does not, they see earnings held up by habit and hope.

The unrealized side matters just as much. The average solo practice leaves $147K a year unrealized, demand that exists in its market but flows elsewhere. You might read that as a problem. A sophisticated buyer reads it as their upside: patient flow they will capture after closing with infrastructure you never built. Either way it gets priced, and the only question is who gets paid for it. You, through a stronger multiple. Or them, through a discount you financed with inaction.

Why does owner dependence quietly cut your price?

Run the test the buyer runs: subtract yourself. If you produce more than half the dentistry, hold the key referral relationships, and are the reason the front desk runs, then the asset being sold is you, and you are the one thing that cannot transfer.

Owner dependence shows up in the structure of the offer before it shows up in the price. Heavier earnouts. Longer mandatory workback periods. More of your proceeds contingent on targets you will be hitting as an employee inside someone else's system. The headline number can look respectable while the guaranteed portion quietly shrinks.

The escape is not hiring an associate the year you sell. It is making patient demand attach to the practice rather than the person. A pattern worth sitting with: AI-referred patients book high-value treatment at 2-3x the rate of other channels, and those patients chose a practice an engine recommended, not a doctor a neighbor praised. Demand that arrives through visibility is demand that survives your exit. That is precisely why buyers have started auditing it, and why practices that own their visibility negotiate from a different chair.

How do high-value service lines change the math?

Buyers pay for where the market is going, and the growth is concentrated in exactly the dentistry that carries the highest tickets. Implants are growing 8.5% a year at a $4,500 average case value. Cosmetic runs at 6.8% and $3,800. Ortho grows 5.1% at $5,500 per case. If you hold real volume in these lines, you are not just earning more per chair hour. You are holding a position in the segments a DSO's own growth model depends on, and buyers pay for positions they would otherwise have to build.

But volume alone is not the asset. The diligence question is whether the high-value flow is systematic: do implant patients find you, or do you convert them one at a time out of hygiene checks? The gap between those two practices shows up in every signal a buyer can pull:

The Dental Index national practice audit · 2026

Same dentistry. Different delivery system. Different multiple.

How do earnouts and equity rolls change the real number?

The number in the letter of intent is a headline, not a check. A typical structure pays a portion in cash at close, holds a portion in an earnout tied to future performance, and rolls a portion into equity in the parent company. Owners negotiate the headline. Experienced sellers negotiate the mix.

Here is where valuation and visibility collide a second time. Your earnout depends on the practice hitting targets after you have handed over control of almost everything except one thing: the patient demand you built before closing. If your new patient flow rests on durable Maps and AI visibility, you walk into the earnout with momentum the integration process cannot easily break. If it rests on your personal energy, the earnout is a bet against your own exhaustion.

The equity roll runs on the same logic at portfolio scale. The parent's future value is a function of demand capture across every location, which is why acquirers increasingly audit visibility before they buy. You are not just selling a practice. You are buying into a machine, and you should judge that machine by the same standard it just judged you.

What can you change in the 12 to 24 months before a sale?

Not your history, but almost everything a buyer prices. Earnings restatements need a year of clean books to survive. Provider dependence takes time to dilute. And visibility, the newest line in the model, responds faster than either. The average practice sits below 40 out of 100 on AI readiness, which means the bar for standing out is remarkably low, and the 8% scoring above 65 are collecting a premium the rest never see. Your route into that 8% is not spend. It is positioning clarity: a practice that states plainly who it serves, what it does exceptionally, and why an engine should recommend it.

Work backwards from the diligence checklist. Clean the books. Stabilize the hygiene chairs. Then treat your visibility the way a dental positioning expert would: as an asset under construction with a closing date. Every month your practice stays invisible in AI search is a month of demand flowing to a competitor, compounding into their valuation story instead of yours.

The pattern among sellers who start early is not just stronger multiples. It is better structures, shorter workbacks, and earnouts they actually collect. The work is the same either way. The only variable is who profits from it.

Dr. Osei signed fourteen months later. Not on the first offer. On a better one, negotiated after she made the group legible to the systems that price it: clean books, a stable hygiene team, four locations an AI engine could actually find and recommend. The first number was never a judgment of her dentistry, and yours is not a judgment of yours. It is a measurement of what transfers, and in 2026 that measurement runs through screens you may never have checked: the Maps results, the AI answers, the profile a diligence analyst pulls up at 9pm. Positioning clarity is what makes every one of them work in your favor. A practice that is unmistakable about what it is gets found, gets recommended, and gets priced like infrastructure.